Combining Phenylbutyrate and Gemcitabine to Treat Lung Cancer
Author Information
Author(s): Bodo Schniewind, Kirsten Heintz, Roland Kurdow, Ole Ammerpohl, Anna Trauzold, Doris Emme, Peter Dohrmann, Holger Kalthoff
Primary Institution: Schleswig-Holstein University Hospitals, Campus Kiel
Hypothesis
The combination of the HDAC inhibitor phenylbutyrate and gemcitabine will enhance apoptosis in non-small cell lung cancer (NSCLC) cells compared to either drug alone.
Conclusion
The combination therapy significantly reduces tumor cell proliferation and enhances apoptosis in NSCLC, suggesting phenylbutyrate is a promising supplemental treatment.
Supporting Evidence
- Combination therapy was 50–80% more effective than either agent alone.
- The size of tumors in treated mice was significantly reduced compared to those treated with gemcitabine alone.
- Caspase activation was significantly increased with combination therapy.
Takeaway
Using two medicines together can help fight lung cancer better than using just one. It's like having a superhero team instead of just one hero!
Methodology
The study involved dose escalation studies on NSCLC cell lines and an orthotopic animal model to evaluate the effects of the drug combination on apoptosis and tumor growth.
Limitations
The study primarily focused on two cell lines and may not represent all NSCLC types.
Participant Demographics
The study used human lung cancer cell lines and SCID mice for in vivo experiments.
Statistical Information
P-Value
p = 0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website